Recent Quotes
My Watchlist
Indicators
Star 60
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Hutchmed China Ltd ADR (NQ: HCM )

17.27 +0.01 (+0.06%)
Streaming Delayed Price Updated: 12:32 PM EDT, Aug 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 15,768
Open 17.31
Bid (Size) 17.23 (4)
Ask (Size) 17.29 (2)
Prev. Close 17.26
Today's Range 17.18 - 17.72
52wk Range 11.93 - 21.92
Shares Outstanding 871,256,270
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
HUTCHMED to Host Expert Call to discuss Immune Thrombocytopenia
From HUTCHMED (China) Limited
Via GlobeNewswire
Hutchmed scores U.S. success with cancer drug, but profits still dip
Key Takeaways: Hutchmed’s U.S. sales jumped nearly 53% in the second quarter from the previous three months, boosted by uptake of the cancer drug Fruzaqla The company plans to focus on innovative drugs... 
Via Benzinga

Performance

YTD
-1.37%
-1.37%
1 Month
-6.95%
-6.95%
3 Month
-9.82%
-9.82%
6 Month
+10.42%
+10.42%
1 Year
+16.69%
+16.69%

More News

Read More
HUTCHMED Reports 2024 Interim Results and Provides Business Updates
From HUTCHMED (China) Limited
Via GlobeNewswire
Why HUTCHMED Stock Is Moving Higher Friday
Via Benzinga
HUTCHMED Announces NDA Acceptance in China for Tazemetostat for the Treatment of Relapsed or Refractory Follicular Lymphoma with Priority Review Status
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED to Announce 2024 Half-Year Financial Results
From HUTCHMED (China) Limited
Via GlobeNewswire
Save the Date: HUTCHMED to Present R&D Updates on July 9, 2024
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED Highlights Publication of Phase III ESLIM-01 Results in The Lancet Haematology
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological Malignancies in China
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED Highlights Publication of Phase III FRUTIGA Results in Nature Medicine
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED Highlights Presentations at the 2024 ASCO Annual Meeting
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED announces retirement of Chairman, appointment of new Chairman and change of members of board committees
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be Presented at the upcoming EHA2024 Congress
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED Initiates the RAPHAEL Registrational Phase III Trial of HMPL-306 for Patients with IDH1- and/or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia in China
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui
From HUTCHMED (China) Limited
Via GlobeNewswire
Spectrum Brands Posts Upbeat Results, Joins AerSale, Sinclair, ICU Medical And Other Big Stocks Moving Higher On Thursday
Via Benzinga
HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda
From HUTCHMED (China) Limited
Via GlobeNewswire
Week In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billion
Via Talk Markets
HUTCHMED Highlights Data to be Presented at AACR Congress 2024
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status
From HUTCHMED (China) Limited
Via GlobeNewswire
HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC
From HUTCHMED (China) Limited
Via GlobeNewswire
Hello Group Posts Q4 Results, Joins SentinelOne, Futu Holdings And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
Topics Stocks
Exposures US Equities
Why Clover Health Investments Shares Are Trading Higher By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.